“Historic” cisplatin shortage leaves oncologists guessing whether they will have enough to treat the next patient

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone. The work will be presented at the 2024 ASCO Annual Meeting.

May 31, 2024

Vol.50 No.22

Clinical Roundup

UCLA study: Combination of breast cancer and chemo may speed physical decline in older adults

Women who are 65 years old or older with high-risk breast cancer and are treated with chemotherapy are more likely to develop a substantial decline in physical function, a UCLA-led study suggests.

May 17, 2024

Vol.50 No.20

Drugs & Targets

FDA, EMA grant Orphan Drug Designation to Carthera for carboplatin with SonoCloud technology in glioma

FDA and the European Medicines Agency granted an Orphan Drug Designation to Carthera for the use of carboplatin when used with SonoCloud technology in the treatment with malignant glioma.

May 17, 2024

Vol.50 No.20

Drugs & Targets

FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products

FDA has approved safety labeling changes for fluorouracil injection products. This effort was a collaboration between FDA’s Office of Generic Drugs and the Oncology Center of Excellence.

March 22, 2024

Vol.50 No.12

In Brief

FTC launches investigation of the roles GPOs, wholesalers play in causing drug shortages

The Federal Trade Commission has launched an investigation into the role of hospital group purchasing organizations and dominant wholesalers in causing decades-long shortages of hundreds of lifesaving drugs.

February 16, 2024

Vol.50 No.07

Clinical Real-world Evidence

Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study shows
FDA says raw images enrich the data when used with clinician assessments

A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.

October 06, 2023

Vol.49 No.37

By Matthew Bin Han Ong

“Historic” cisplatin shortage leaves oncologists guessing whether they will have enough to treat the next patient

YOU MAY BE INTERESTED IN

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

UCLA study: Combination of breast cancer and chemo may speed physical decline in older adults

FDA, EMA grant Orphan Drug Designation to Carthera for carboplatin with SonoCloud technology in glioma

FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products

FTC launches investigation of the roles GPOs, wholesalers play in causing drug shortages

Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study shows
FDA says raw images enrich the data when used with clinician assessments

Renew today!

Subscriber content

Login

“Historic” cisplatin shortage leaves oncologists guessing whether they will have enough to treat the next patient

YOU MAY BE INTERESTED IN

Combination therapy improves PFS, OS for metastatic colorectal cancer in phase Ib/II study

UCLA study: Combination of breast cancer and chemo may speed physical decline in older adults

FDA, EMA grant Orphan Drug Designation to Carthera for carboplatin with SonoCloud technology in glioma

FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products

FTC launches investigation of the roles GPOs, wholesalers play in causing drug shortages

Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study showsFDA says raw images enrich the data when used with clinician assessments

Login

Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study shows
FDA says raw images enrich the data when used with clinician assessments